false
0001445815
0001445815
2026-11-04
2026-11-04
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT PURSUANT TO SECTION 13 OR 15(d)
OF
THE SECURITIES EXCHANGE ACT OF 1934
Date
of Report (Date of earliest event reported): November 4, 2026
BIOXYTRAN,
INC.
(Exact
Name of Registrant as Specified in Charter)
| Nevada |
|
001-35027 |
|
26-2797630 |
| (State
or Other Jurisdiction |
|
(Commission |
|
(IRS
Employer |
| of
Incorporation) |
|
File
Number) |
|
Identification
Number) |
| 75
Second Ave, Suite 605, Needham, MA |
|
02494 |
| (Address
of Principal Executive Offices) |
|
(Zip
Code) |
Registrant’s
telephone number, including area code 617-454-1199
(Former
Name or Former Address, if Changed Since Last Report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (see General Instruction A.2. below):
| ☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
|
| ☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
|
| ☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| |
|
| ☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
| Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
| Common
Stock, par value $0.001 |
|
BIXT |
|
OTCQB |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
Growth Company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item
8.01. Other Events
On
November 4, 2026, the Company issued a press-release over Globe Newswire, enclosed hereto as Exhibit 99.1, under the title:
Bioxytran
Secures Attested Free Sale Certification for A-SUQAR®, Opening the Path to the UAE and Gulf Markets
Item
9.01 Financial Statements and Exhibits.
Exhibit
Number |
|
Description |
| |
|
|
| 99.1* |
|
Press Release dated November 4, 2026, entitled “Bioxytran Secures Attested Free Sale Certification for A-SUQAR®, Opening the Path to the UAE and Gulf Markets”. |
| |
|
|
| 104 |
|
Cover
Page Interactive Data File (embedded within the Inline XBRL document) |
| * |
Filed
as an exhibit hereto. |
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
| |
BIOXYTRAN,
INC. |
| |
|
|
| |
By: |
/s/
David Platt, Ph.D. |
| |
|
David
Platt, Ph.D., its Chief Executive Officer |
| |
|
|
| Date
November 4, 2026 |
|
|
Exhibit 99.1
Bioxytran
Secures Attested Free Sale Certification for A-SUQAR®, Opening the Path to the UAE and Gulf Markets
Non-systemic,
pre-meal chewable nutraceutical designed to help blunt post-meal blood sugar spikes enters a region where roughly 7.5 million adults
in the UAE, Saudi Arabia and Kuwait are living with diabetes
Boston,
MA — November 4, 2026 — Bioxytran, Inc. (OTCQB: BIXT), a biotechnology company developing galectin-targeting carbohydrate
technologies with applications across infectious disease, metabolic health and inflammation, today announced that its A-SUQAR®
® tablet has received a government-issued Free Sale Certificate, which has been legalized by the issuing country’s Ministry
of Foreign Affairs and prepared for attestation for use in the United Arab Emirates. The certification confirms that A-SUQAR®
is lawfully manufactured and freely sold as a food and health supplement and is a key regulatory document for product registration and
market entry in the UAE and the wider Gulf Cooperation Council (GCC) region.
A
region facing one of the world’s heaviest diabetes burdens
The
Gulf is among the regions most affected by diabetes worldwide. According to the International Diabetes Federation (IDF) Diabetes Atlas,
11th Edition (2025):
| ● | United
Arab Emirates: approximately 1.27 million adults (aged 20–79) are living
with diabetes, an age-standardized prevalence of 20.7%. An estimated 64% of
those cases are undiagnosed. |
| ● | Saudi
Arabia: approximately 5.34 million adults are living with diabetes (age-standardized
prevalence 23.1%), a figure projected to rise to 9.5 million by 2050. |
| ● | Kuwait:
approximately 908,500 adults are living with diabetes (age-standardized prevalence
25.6%), giving Kuwait one of the highest diabetes prevalence rates in the world. |
Together,
these three countries account for roughly 7.5 million adults with diabetes. Across the IDF Middle East and North Africa (MENA)
region, 84.7 million adults were living with diabetes in 2024, a number expected to grow by 92% to 162.6 million by 2050.
The region has the highest diabetes prevalence of any IDF region, and about one in three adults with diabetes have not been diagnosed.
A
non-systemic approach to post-meal blood sugar
A-SUQAR®
is a chewable tablet taken before meals. Rather than acting systemically to lower blood sugar, A-SUQAR® works locally only in the
digestive tract. Its formulation, built on Bioxytran’s proprietary polysaccharides technology, is designed to slow the activity
of the intestinal enzymes that break down dietary carbohydrates into glucose. By slowing carbohydrate digestion, A-SUQAR®
helps sugars enter the bloodstream more gradually, supporting healthier post-meal blood sugar levels and helping to avoid the sharp spikes
that follow carbohydrate-rich meals.
Because
it acts in the gut rather than throughout the body, A-SUQAR® is positioned as a complement to diet, exercise and physician-directed
care for people seeking to manage the carbohydrate load of everyday meals.
“The
Gulf region has some of the highest rates of diabetes anywhere in the world, and post-meal blood sugar spikes are a daily challenge for
millions of people there,” said David Platt, Ph.D., Chief Executive Officer of Bioxytran. “Securing this attested Free Sale
Certificate is an important step toward bringing A-SUQAR® to consumers in the UAE and neighboring markets. A-SUQAR®
reflects our expertise in carbohydrate science, offering a simple, non-systemic option taken right before a meal.”
Next
steps
With
the attested Free Sale Certificate in hand, Bioxytran and its commercial distribution partner intend to proceed with product registration
in the UAE and to evaluate registration pathways in Saudi Arabia, Kuwait and other GCC markets. Timing for the commercial launch in each
market will depend on the completion of local regulatory requirements.
U.S.
regulatory status
In
the United States, A-SUQAR® is regulated as a dietary supplement. A-SUQAR® ‘s has structure and function
claims and supporting safety information by the U.S. Food and Drug Administration (FDA). The FDA does not approve dietary supplements
or their structure/function claims before they are marketed; A-SUQAR® is in compliances with U.S. dietary supplement requirements.
About
Bioxytran, Inc.
Bioxytran,
Inc. (OTCQB: BIXT) is a biotechnology company developing galectin-targeting carbohydrate technologies with applications across infectious
disease, metabolic health and inflammation. The company’s lead drug candidate, ProLectin-M, is being developed as a broad-spectrum
antiviral. For more information, visit www.bioxytraninc.com.
Important
information
These
statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent
any disease.
A-SUQAR®
is a dietary supplement and is not a substitute for prescribed diabetes medication. People with diabetes or other medical conditions
should consult a healthcare professional before use. Product availability and permitted claims vary by market and are subject to local
regulatory requirements.
Forward-Looking
Statements
This
press release contains forward-looking statements within the meaning of applicable federal securities laws, including statements regarding
product registration, regulatory approvals, the anticipated commercialization of A-SUQAR® ® in the UAE and other GCC
markets, and the expected benefits of the product. These statements are subject to risks, uncertainties and assumptions that could cause
actual results to differ materially, including those described in the company’s filings with the U.S. Securities and Exchange Commission.
Bioxytran undertakes no obligation to update or revise any forward-looking statements, except as required by applicable law.
Media
and Investor Contact
David
Platt, PhD/CEO
Bioxytran,
Inc.
Info@bioxytraninc.com
Phone:
617.454.1199
www.bioxytraninc.com
